The studys methodology and findings revealed data points: Among 710 type 2 diabetes patients, 17 semaglutide users developed NAION versus only 6 non-users, despite similar baseline characteristics In the weight loss cohort of 979 patients, NAION occurred in 20 semaglutide users compared to 3 in the control group Cumulative NAION incidence over 36 months reached 8.9% for diabetic semaglutide users versus 1.8% for non-GLP-1 medications Weight loss patients showed 6.7% NAION incidence with semaglutide versus 0.8% without Manual chart review by neuro-ophthalmology specialists ensured diagnostic accuracy often lacking in larger database studies Risk persisted after controlling for known NAION risk factors including age, sex, hypertension, and sleep apnea The biological plausibility of semaglutide-induced NAION stems from multiple proposed mechanisms that researchers continue investigating

Some trials have shown that participants lost a higher percentage of body weight with tirzepatide than with a similar treatment over a similar treatment period
Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity
R.AdachiJ.AsanoM.KollM.MantleD.NiemelaO.et al (2002)
Tin s Jake Violi ca trng UNSW cho bit, "chc chn" khng c GLP-1 hoc bt k phn t thuc no khc c th nhn dng c trong mu, mu ny rt mn v c v "ch l thuc nh mt hoc mt s sn phm tng t"
But movement is still important